Zhi Tong Cai Jing·2026-01-12 12:07Core Viewpoint - WuXi AppTec (药明康德) anticipates an increase in revenue and net profit for the fiscal year ending December 31, 2025, compared to the same period in 2024, driven by its integrated CRDMO business model and strategic asset sales [1][2]. Group 1: Financial Performance - The company expects to achieve revenue of approximately RMB 45,456.17 million, representing a year-on-year growth of about 15.84%, with a 21.40% increase in revenue from continuing operations [1]. - Adjusted net profit attributable to shareholders is projected to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, is expected to be about RMB 13.241 billion, with a year-on-year increase of approximately 32.56% [1]. - The total net profit attributable to shareholders is anticipated to be around RMB 19.151 billion, showing a significant year-on-year growth of approximately 102.65% [1]. - Basic earnings per share are expected to be approximately RMB 6.70, representing a year-on-year increase of about 104.27% [1]. Group 2: Business Strategy and Operations - The company continues to focus on its unique "integrated, end-to-end" CRDMO business model, enhancing capabilities and building new production capacity to meet customer demands [2]. - The impact of non-recurring gains on net profit primarily stems from the sale of a portion of its stake in WuXi XDC Cayman Inc., expected to yield a net gain of approximately RMB 4.161 billion, and the sale of 100% stakes in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd., expected to yield a net gain of approximately RMB 1.434 billion [2].